Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn's Disease: A Prospective Observational Study.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Louis Edouard, Sebastian Shaji, Siegmund Britta, Bossuyt Peter, Danese Silvio, de Boer Nanne, Loftus Edward V, Moum Bjørn, Peyrin-Biroulet Laurent, Schreiber Stefan, Zhou Jie, Angellotti Edith, Adsul Shashi, Jones Stephen, Siegel Corey A
Аннотация
BACKGROUND & AIMS: This postauthorization safety study compared long-term safety of vedolizumab or other biologics in patients with ulcerative colitis (UC) or Crohn's disease (CD).
METHODS: This was a prospective, observational, multicenter cohort study in patients with UC or CD starting treatment with vedolizumab or other biologics (NCT02674308, EUPAS6469). The primary safety outcome was serious infections compared between cohorts using a Cox proportional hazards model adjusted by propensity score. Clinical effectiveness was a secondary outcome.
RESULTS: The full analysis set comprised 5008 patients (vedolizumab: n = 2502; other biologic: n = 2506) and mean follow-up duration was 37.4 ± 14.1 months. Patients in the vedolizumab group had greater age, duration of disease, and concomitant medication use at baseline, indicating more advanced disease. In patients with UC, the incidence rate per 100 person-years of serious infections was 5.5 (95% confidence interval [CI], 4.7-6.5) (vedolizumab) and 7.0 (95% CI, 5.8-8.5) (other biologic), with an adjusted hazard ratio of 0.89 (95% CI, 0.69-1.15) (P = .38). In patients with CD, corresponding findings were 7.9 (95% CI, 6.8-9.1) (vedolizumab) and 6.5 (95% CI, 5.7-7.3) (other biologic) with adjusted hazard ratio of 1.15 (95% CI, 0.95-1.40) (P = .16). There were no safety issues relating to pregnancy, and no cases of progressive multifocal leukoencephalopathy were observed. There were 18 deaths in the vedolizumab group and 13 in the other biologics group. Clinical effectiveness was comparable between cohorts and was similar to the levels seen in other prospective observations of vedolizumab.
CONCLUSIONS: There was no new safety signal identified in relation to vedolizumab. Results regarding safety and effectiveness were consistent with the known profile of vedolizumab.
METHODS: This was a prospective, observational, multicenter cohort study in patients with UC or CD starting treatment with vedolizumab or other biologics (NCT02674308, EUPAS6469). The primary safety outcome was serious infections compared between cohorts using a Cox proportional hazards model adjusted by propensity score. Clinical effectiveness was a secondary outcome.
RESULTS: The full analysis set comprised 5008 patients (vedolizumab: n = 2502; other biologic: n = 2506) and mean follow-up duration was 37.4 ± 14.1 months. Patients in the vedolizumab group had greater age, duration of disease, and concomitant medication use at baseline, indicating more advanced disease. In patients with UC, the incidence rate per 100 person-years of serious infections was 5.5 (95% confidence interval [CI], 4.7-6.5) (vedolizumab) and 7.0 (95% CI, 5.8-8.5) (other biologic), with an adjusted hazard ratio of 0.89 (95% CI, 0.69-1.15) (P = .38). In patients with CD, corresponding findings were 7.9 (95% CI, 6.8-9.1) (vedolizumab) and 6.5 (95% CI, 5.7-7.3) (other biologic) with adjusted hazard ratio of 1.15 (95% CI, 0.95-1.40) (P = .16). There were no safety issues relating to pregnancy, and no cases of progressive multifocal leukoencephalopathy were observed. There were 18 deaths in the vedolizumab group and 13 in the other biologics group. Clinical effectiveness was comparable between cohorts and was similar to the levels seen in other prospective observations of vedolizumab.
CONCLUSIONS: There was no new safety signal identified in relation to vedolizumab. Results regarding safety and effectiveness were consistent with the known profile of vedolizumab.